Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Gene Transfer of rAAVrh74.MCK.micro-Dystrophin in DMD
NCT02376816Phase 1Completed
- Start
- Mar 2015
- Primary completion
- Sep 2017
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of delandistrogene moxeparvovec in Duchenne muscular dystrophy (DMD) (2 cohorts). Primary endpoint: Safety based on number of participants with adverse events at 2 years. Started Mar 2015; status: completed.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02376816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02376816.